The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.
The sexually transmitted infection are on the rise around the world, with estimates suggesting more than 82 million infections annually. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.
“The approval of novel therapies for gonorrhoea is an significant and necessary step in the face of growing infection rates, escalating drug resistance and the highly restricted available drugs presently on offer.”
Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.
Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that focused deployment of this new drug will help hinder the emergence of superbugs.
Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.
This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.
“This milestone represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”
As per data released by a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The study enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.
Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.
Doctors treating patients have voiced positive views. Access to a single-dose, oral treatment such as this is described as a "revolutionary step" for public health efforts. This is deemed essential to alleviate the strain of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.
Elara is a passionate writer and photographer who shares insights on creativity and mindful living through engaging storytelling.
